BSE filing, NSE: LAOPALA. Summary written from the filing by ALFA Finder's alert engine.
La Opala RG Ltd: key numbers
- Share price
- ₹140.98
- Market cap
- ₹1,565 Cr
- Revenue (annual)
- ₹309.1 Cr
- Net profit (annual)
- ₹92.30 Cr
- P/E (TTM)
- 16.8×Sector 42.1×
- Promoter holding
- 66.51%+0.23% QoQ
- FII holding
- 0.41%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from La Opala RG Ltd
All →La Opala RG Other Announcement
La Opala RG Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required by SEBI Regulation 31(1)(b).
La Opala RG Promoter Buying: ₹0.78 Cr
La Opala RG promoter Genesis Exports acquired 50,000 shares on NSE for Rs. 0.78 Crore. Promoter stake rose from 47.25% to 47.30%.
- Value
- ₹0.78 Cr
- Promoter stake change
- +0.05%
La Opala RG Promoter Buying: ₹3.21 Cr
Promoter Genesis Exports Private Limited acquired 2,00,000 equity shares of La Opala RG Ltd for ₹3.21 Crore via an on-market transaction.
- Value
- ₹3.21 Cr
- Promoter stake change
- +0.18%
La Opala RG Promoter Buying
Genesis Exports Private Limited, a promoter of La Opala RG Limited, acquired 2,00,000 shares (0.18% stake) via open market purchases.
- Promoter stake change
- +0.18%
La Opala RG Other Announcement
Crisil ESG Ratings has voluntarily assigned an ESG rating of 'Crisil ESG 58' to La Opala RG Limited. The rating was based on fiscal year 2026 public disclosures.
La Opala RG Annual General Meeting
La Opala RG Limited concluded its 39th Annual General Meeting today. The meeting transacted ordinary and special businesses, including the declaration of a final dividend.
Other board meeting date announcements
All →Patel Engineering Board Meeting Date
Patel Engineering has scheduled its Board meeting for November 5, 2026, to approve Q1 and H1 FY27 unaudited results. No financial figures or decisions are reported in this advance notice.
GKB Ophthalmics Board Meeting Date
GKB Ophthalmics scheduled its Board Meeting for November 12, 2026. The meeting will consider approving unaudited results for the September 30, 2026 quarter and half year.
Bombay Oxygen Investments Board Meeting Date
Board meeting scheduled for Nov 6, 2026 to approve Q1 and H1 FY27 unaudited results. Trading window closed for insiders Oct 1–Nov 8, 2026.
OCCL Board Meeting Date
OCCL Ltd has scheduled its Board meeting for 6 November 2026 to consider Q1 FY27 unaudited results and a possible interim dividend. The trading window for designated persons closed from 1 October 2026.
TCM Board Meeting Date
TCM Limited intimated a Board meeting for 06/11/2026 to approve Q2 FY27 results. The trading window will reopen 48 hours after the results declaration.
Mercury Laboratories Board Meeting Date
Mercury Laboratories scheduled its Board meeting for November 5, 2026, to approve Q2/H1 FY27 results. Trading window remains closed until 48 hours post-announcement.